An investigation on behalf of investors in OpGen, Inc. (NASDAQ:OPGN) shares over potential wrongdoing at OpGen, Inc. was announced.
San Diego, CA — (SBWIRE) — 02/15/2022 — Certain directors of OpGen, Inc are under investigation concerning potential breaches of fiduciary duties.
Investors who purchased shares of OpGen, Inc. (NASDAQ: OPGN) have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
Rockville, MD based OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. OpGen, Inc. reported that its annual Total Revenue rose from $3.49 million in 2019 to $4.21 million in 2020, and that its Net Loss increased from $12.44 million in 2019 to $26.21 million in 2020.
Shares of OpGen, Inc. (NASDAQ: OPGN) declined from $3.55 per share in early 2021 to as low as $0.78 per share on January 24, 2022.
Those who purchased shares of OpGen, Inc. (NASDAQ: OPGN) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit: http://www.sbwire.com/press-releases/opgen-inc-nasdaqopgn-investor-alert-investigation-potential-wrongdoing-1353308.htm
Media Relations Contact